Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has earned a consensus rating of “Hold” from the twelve brokerages that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, five have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $26.57.
A number of equities research analysts have recently commented on VNDA shares. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Friday, August 2nd. Oppenheimer set a $18.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “hold” rating in a report on Sunday, May 5th. ValuEngine upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Citigroup upgraded shares of Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $19.00 price target for the company in a report on Thursday, August 1st. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $17.00 price target on shares of Vanda Pharmaceuticals in a report on Wednesday, July 31st.
VNDA traded up $0.08 during midday trading on Friday, reaching $14.88. 12,318 shares of the company’s stock were exchanged, compared to its average volume of 912,405. The firm has a market cap of $801.24 million, a PE ratio of 30.96 and a beta of 0.38. The company’s 50-day moving average price is $13.87. Vanda Pharmaceuticals has a 1-year low of $11.83 and a 1-year high of $33.44.
In related news, CEO Mihael Hristos Polymeropoulos sold 72,872 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $15.34, for a total value of $1,117,856.48. Following the completion of the sale, the chief executive officer now directly owns 1,276,343 shares in the company, valued at $19,579,101.62. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 8.20% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the stock. Advisor Group Inc. lifted its position in Vanda Pharmaceuticals by 66.2% during the fourth quarter. Advisor Group Inc. now owns 2,916 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 1,161 shares in the last quarter. Pearl River Capital LLC lifted its position in Vanda Pharmaceuticals by 6,148.0% during the first quarter. Pearl River Capital LLC now owns 6,248 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 6,148 shares in the last quarter. O Shaughnessy Asset Management LLC acquired a new position in Vanda Pharmaceuticals during the first quarter valued at approximately $117,000. Adams Diversified Equity Fund Inc. acquired a new position in Vanda Pharmaceuticals during the first quarter valued at approximately $120,000. Finally, Pacer Advisors Inc. acquired a new position in Vanda Pharmaceuticals during the second quarter valued at approximately $138,000. Hedge funds and other institutional investors own 99.33% of the company’s stock.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Recommended Story: Equal Weight Rating
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.